Table 4.
Univariate and multivariate predictors of overall survival.
| Variables | Univariate Cox analysis | Multivariate Cox analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Sex (men/women) | 1.638 | 0.712-3.768 | 0.246 | |||
| Age (years) (<50/≥50) | 0.620 | 0.325-1.183 | 0.147 | 2.052 | 1.040-4.048 | 0.038 |
| ECOG PS (0 + 1/2) | 2.328 | 0.811-6.683 | 0.116 | 0.473 | 0.159-1.413 | 0.180 |
| HBV infection (negative/positive) | 1.111 | 0.433-2.852 | 0.827 | |||
| Cirrhosis (yes/no) | 1.211 | 0.687-1.821 | 0.649 | |||
| Child–Pugh class (A/B) | 0.778 | 0.383-1.577 | 0.486 | |||
| AFP (ng/mL) (<400/≥400) | 1.344 | 0.687-2.631 | 0.388 | |||
| Tumor size (cm) (<10/≥10) | 0.786 | 0.415-1.489 | 0.461 | |||
| Extrahepatic metastasis (yes/no) | 1.298 | 0.795-2.157 | 0.298 | |||
| PVTT (type I+II/III) | 0.456 | 0.452-1.461 | 0.736 | |||
| Albumin level (g/L) (<35/≥35) TBIL (μmol/L) (<20/≥20) ALT (U/L) (<35/≥35) AST (U/L) (<40/≥40) Number of TACE (1/2+3) |
1.135 1.083 0.636 1.271 0.590 |
0.594-2.167 0.554-2.116 0.333-1.217 0.530-3.050 0.307-1.133 |
0.702 0.816 0.172 0.592 0.113 |
1.609 |
0.807-3.208 |
0.176 |
| Treatment (T+S+ICIs/T+S) | 0.426 | 0.222-0.820 | 0.011 | 0.386 | 0.195-0.764 | 0.006 |
ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus; type I, tumor thrombi involving segmental branches of portal vein or above; type II, tumor thrombi involving right/left portal vein; type III, tumor thrombi involving the main portal vein; TBIL, total bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors.